Simple Summary Diffuse large B-cell lymphoma (DLBCL) with co-expression of MYC and
BCL2 proteins is referred to as double expressor lymphoma. Multiple studies have identified …

Diffuse large B-cell lymphoma (DLBCL) is an aggressive disease with considerable
heterogeneity reflected in the 2008 World Health Organization classification. In recent years …

Acute lymphoblastic leukemia (ALL) is an aggressive leukemia which can be derived from
either T-cell or B-cell precursors. With current treatments, the survival rate is high, but the …

Objective We evaluated the clinical implications of the albumin to globulin ratio (AGR) in
patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab …

Background We assessed the prognostic significance of pretreatment C-reactive protein
(CRP) concentration in diffuse large B-cell lymphoma (DLBCL) patients. Methods We …

Background The pretreatment albumin to globulin ratio (AGR) has been used to predict
survival in several types of tumors. However, whether AGR can predict outcomes in patients …

Background The treatment of high‐risk B‐cell lymphoma (BCL) remains a challenge,
especially in the elderly. Methods A total of 83 patients (median age 65 years), who have …

Background Many studies have shown that c-Myc plays a critical role in tumorigenesis.
However, the molecular role of c-Myc in head and neck squamous cell carcinoma (HNSC) …

Purpose We estimated the expression of nuclear factor kappa B/p65 in non-germinal center
B-cell-like subtype diffuse large B-cell lymphoma, to investigate its relationship to …

Purpose The aim was to explore whether baseline total lesion glycolysis (TLG) can improve
the prognostic value of the National Comprehensive Cancer Network International …